Rhenman & Partners Asset Management Ab Akero Therapeutics, Inc. Transaction History
Rhenman & Partners Asset Management Ab
- $766 Million
- Q2 2025
A detailed history of Rhenman & Partners Asset Management Ab transactions in Akero Therapeutics, Inc. stock. As of the latest transaction made, Rhenman & Partners Asset Management Ab holds 197,600 shares of AKRO stock, worth $10.7 Million. This represents 1.38% of its overall portfolio holdings.
Number of Shares
197,600
Previous 92,500
113.62%
Holding current value
$10.7 Million
Previous $3.74 Million
181.6%
% of portfolio
1.38%
Previous 0.45%
Shares
2 transactions
Others Institutions Holding AKRO
# of Institutions
299Shares Held
92.3MCall Options Held
1.72MPut Options Held
901K-
Janus Henderson Group PLC London, X06.74MShares$364 Million0.19% of portfolio
-
General Atlantic LLC New York, NY5.73MShares$310 Million10.64% of portfolio
-
Black Rock Inc. New York, NY5.59MShares$302 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY5.48MShares$296 Million4.49% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.53MShares$245 Million0.0% of portfolio
About Akero Therapeutics, Inc.
- Ticker AKRO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,417,600
- Market Cap $2.51B
- Description
- Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...